Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorde…
$1.51+13.53%
报价 2026-11-06
市值
$95.7M
EV
$39.2M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -52.8%
$0.84$3.20
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| EQEquillium, Inc. | $95.7M | +13.5% | +41.8% | 0% | – | – | – | |
| IPSCCentury Therapeutics, Inc. | $304.2M | +11.3% | -95.7% | 0% | – | – | – | |
| CUECue Biopharma, Inc. | $136.1M | +4.0% | -84.6% | 99.7% | – | – | – | |
| SPRBSpruce Biosciences, Inc. | $133.8M | +9.0% | +2590.0% | 0% | – | – | – | |
| OTLKOutlook Therapeutics, Inc. | $106.2M | -0.6% | +173.6% | 195.6% | – | – | – | |
| NRXPNRx Pharmaceuticals, Inc. | $103M | +4.8% | +800.8% | 32.7% | – | – | – | |
| FBIOFortress Biotech, Inc. | $61.7M | +0.5% | +31.4% | 64.5% | 1.0x | – | 0.8x | |
| TELOTelomir Pharmaceuticals, Inc. Common Stock | $52.3M | -9.0% | -99.9% | 0% | – | – | – | |
| OSTXOS Therapies Incorporated | $46.8M | +2.0% | -84.7% | 0% | – | – | – | |
| 同行中位数 | – | – | -26.6% | 16.3% | 1.0x | – | 0.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。